PT2315773T - Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente - Google Patents

Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente

Info

Publication number
PT2315773T
PT2315773T PT97810527T PT09781052T PT2315773T PT 2315773 T PT2315773 T PT 2315773T PT 97810527 T PT97810527 T PT 97810527T PT 09781052 T PT09781052 T PT 09781052T PT 2315773 T PT2315773 T PT 2315773T
Authority
PT
Portugal
Prior art keywords
tubeculosis
polynucleotides
polypeptides
latent
compositions
Prior art date
Application number
PT97810527T
Other languages
English (en)
Portuguese (pt)
Inventor
Brown James
Mettens Pascal
Murphy Dennis
Original Assignee
Glaxosmithkline Biologicals Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biologicals Sa
Publication of PT2315773T publication Critical patent/PT2315773T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
PT97810527T 2008-07-25 2009-07-24 Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente PT2315773T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
PT2315773T true PT2315773T (pt) 2016-11-23

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97810527T PT2315773T (pt) 2008-07-25 2009-07-24 Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente

Country Status (24)

Country Link
US (2) US20110117119A1 (enExample)
EP (1) EP2315773B1 (enExample)
JP (1) JP5873332B2 (enExample)
KR (1) KR20110044883A (enExample)
CN (1) CN102164952B (enExample)
AU (1) AU2009273130B2 (enExample)
BR (1) BRPI0916703A2 (enExample)
CA (1) CA2731499C (enExample)
CO (1) CO6341637A2 (enExample)
CY (1) CY1118200T1 (enExample)
DK (1) DK2315773T3 (enExample)
EA (1) EA024826B1 (enExample)
ES (1) ES2602430T3 (enExample)
HR (1) HRP20161458T1 (enExample)
HU (1) HUE031044T2 (enExample)
IL (1) IL210559A0 (enExample)
LT (1) LT2315773T (enExample)
MX (1) MX2011000983A (enExample)
PL (1) PL2315773T3 (enExample)
PT (1) PT2315773T (enExample)
SG (1) SG192456A1 (enExample)
SI (1) SI2315773T1 (enExample)
UA (1) UA107330C2 (enExample)
WO (1) WO2010010177A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6480999A (en) * 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
BRPI0916705A2 (pt) 2008-07-25 2015-11-10 Glaxo Group Ltd polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo.
PT2315834T (pt) 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
KR20170072366A (ko) 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
HUE039618T2 (hu) 2013-09-27 2019-01-28 Codexis Inc Enzimvariánsok automatizált szûrése
EP3049979B1 (en) * 2013-09-27 2020-01-01 Codexis, Inc. Structure based predictive modeling
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
MA55628A (fr) 2019-04-12 2022-02-16 C4 Therapeutics Inc Agents de dégradation tricycliques d'ikaros et d'aiolos
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
KR100797876B1 (ko) * 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE60139963D1 (de) * 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
US20040121322A9 (en) * 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
CA2836319A1 (en) * 2005-06-23 2006-12-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
KR20170072366A (ko) * 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген

Also Published As

Publication number Publication date
CA2731499A1 (en) 2010-01-28
HUE031044T2 (en) 2017-06-28
US20110117119A1 (en) 2011-05-19
IL210559A0 (en) 2011-03-31
AU2009273130B2 (en) 2014-10-16
HRP20161458T1 (hr) 2016-12-16
AU2009273130A1 (en) 2010-01-28
DK2315773T3 (en) 2016-12-12
US20140178423A1 (en) 2014-06-26
UA107330C2 (uk) 2014-12-25
CY1118200T1 (el) 2017-06-28
PL2315773T3 (pl) 2017-07-31
JP5873332B2 (ja) 2016-03-01
CN102164952A (zh) 2011-08-24
SG192456A1 (en) 2013-08-30
BRPI0916703A2 (pt) 2019-12-24
JP2011528895A (ja) 2011-12-01
CA2731499C (en) 2017-01-10
EP2315773A1 (en) 2011-05-04
CN102164952B (zh) 2016-05-25
MX2011000983A (es) 2011-03-02
SI2315773T1 (sl) 2016-12-30
CO6341637A2 (es) 2011-11-21
US9795663B2 (en) 2017-10-24
EP2315773B1 (en) 2016-08-24
WO2010010177A1 (en) 2010-01-28
KR20110044883A (ko) 2011-05-02
EA024826B1 (ru) 2016-10-31
EA201100072A1 (ru) 2011-10-31
ES2602430T3 (es) 2017-02-21
LT2315773T (lt) 2016-11-10

Similar Documents

Publication Publication Date Title
PL2315773T3 (pl) Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
PL1975226T3 (pl) Płynna kompozycja do obróbki
EP2314278A4 (en) HAIR TREATMENT COMPOSITION
IL207096A0 (en) Modified leptin polypeptides and their uses
IL213365A (en) Imidazopyrazine and their pharmaceutical preparations
ZA201003899B (en) Novel dosage and formulation
IL195152A (en) Compounds for use in treating diseases of cell culture
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
PL2190405T3 (pl) Kompozycje do traktowania włosów
IL215592A (en) Compounds, preparations containing them and their uses in the treatment or prevention of conditions in the eyes
GB0719202D0 (en) Compositions and methods for the skin and hair
PL2209458T3 (pl) Kompozycje do traktowania skóry
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
MX303262B (es) Composicion de locion para uso personal.
ZA200905427B (en) Rasp and cover
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0714500D0 (en) composition and treatment
GB2461611B (en) Composition and use thereof
ZA200807154B (en) Liquid treatment composition
ZA201000469B (en) Therapeutic compositions and the use thereof
GB0622040D0 (en) Skin treatment composition
GB0810409D0 (en) Composition and use thereof
GB0808877D0 (en) Composition and use thereof